Survival Outcomes Similar Regardless of Sorafenib-Sunitinib Sequence in mRCC

The SWITCH trial makes it official: it makes no difference whether patients with metastatic renal cell carcinoma (mRCC) first start on sorafenib and then switch to sunitinib upon progression or vice versa.02/10/2014
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news